You are here

  • Home
  • Archive
  • Volume 4, Issue 2
  • Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study

Article metrics

Article menu

Download PDFPDF

Rheumatoid arthritis
Original article
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study

 

Online download statistics by month:

Online download statistics by month: November 2018 to March 2024

AbstractFullPdf
Nov 2018122120191
Dec 201811511567
Jan 201910410252
Feb 2019696946
Mar 2019686435
Apr 2019414227
May 2019585728
Jun 2019444425
Jul 2019596021
Aug 2019444419
Sep 2019484615
Oct 2019565614
Nov 2019797923
Dec 2019656512
Jan 2020464519
Feb 2020424214
Mar 2020403917
Apr 2020434323
May 202028287
Jun 2020373721
Jul 202055548
Aug 2020332715
Sep 202038338
Oct 202015144
Nov 2020674917
Dec 202035279
Jan 2021343119
Feb 2021242215
Mar 2021434131
Apr 202119179
May 2021171711
Jun 2021222014
Jul 2021171611
Aug 2021161412
Sep 2021181813
Oct 2021171619
Nov 2021221723
Dec 202115146
Jan 2022191712
Feb 2022252414
Mar 2022383713
Apr 2022352811
May 202240368
Jun 202240368
Jul 202230266
Aug 2022534912
Sep 202228299
Oct 2022283115
Nov 202223224
Dec 202221205
Jan 2023232319
Feb 202332310
Mar 2023363612
Apr 2023141322
May 202323197
Jun 202325211
Jul 2023242316
Aug 202331297
Sep 2023995
Oct 2023333114
Nov 202352489
Dec 202364643
Jan 202444296
Feb 202431279
Mar 2024353215
Total257124341182